Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omicron strain inactivated COVID-19 vaccine (Vero cells)
- Development stage
- Unknown
- Lead developer
- China National Biotec
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Omicron strain inactivated COVID-19 vaccine (Vero cells) is a whole-virion inactivated vaccine developed to provide protection against the Omicron variant of SARS-CoV-2. Produced using Vero cell culture technology, the virus is chemically inactivated (typically using beta-propiolactone) to render it non-infectious while preserving the structural integrity of its antigens, including the spike protein. This approach allows the immune system to recognize and mount a response against multiple viral components. Clinical development, including Phase 3 trials in China, has focused on evaluating its safety and immunogenicity as both a primary series in unvaccinated individuals and as a booster dose to address the immune evasion characteristics of the Omicron lineage.
- Other names
- Omicron-specific inactivated COVID-19 vaccineOmicron-specific inactivated vaccine (Vero cells)
02
Targets
Severe acute respiratory syndrome coronavirus 2 Spike protein (Omicron lineage)N (Nucleocapsid protein)BCR (Immunoglobulin G B Cell Receptor)SARS-CoV-2 envelope protein (Omicron lineage)SARS-CoV-2 Membrane protein (Omicron lineage)
Beyond the preview
Go deeper on Omicron strain inactivated COVID-19 vaccine (Vero cells).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omicron strain inactivated COVID-19 vaccine (Vero cells).